Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:ONC NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$105.52-0.7%$104.64$81.20▼$129.27$25.35B1.45948,971 shs114,376 shsINSMInsmed$163.59+1.1%$135.87$60.40▼$164.06$34.58B1.032.71 million shs216,565 shsONCBeOne Medicines$336.98-4.0%$321.31$170.99▼$355.30$36.93B0.31407,632 shs86,267 shsROIVRoivant Sciences$16.24+1.3%$13.26$8.73▼$16.79$11.09B1.26.19 million shs1.16 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+0.21%+3.98%+3.53%-6.71%-11.65%INSMInsmed-0.31%+9.87%+10.31%+67.40%+126.72%ONCBeOne Medicines+2.77%+4.75%+1.34%+38.56%+35,108,999,900.00%ROIVRoivant Sciences-0.56%+1.78%+24.17%+38.55%+42.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$105.52-0.7%$104.64$81.20▼$129.27$25.35B1.45948,971 shs114,376 shsINSMInsmed$163.59+1.1%$135.87$60.40▼$164.06$34.58B1.032.71 million shs216,565 shsONCBeOne Medicines$336.98-4.0%$321.31$170.99▼$355.30$36.93B0.31407,632 shs86,267 shsROIVRoivant Sciences$16.24+1.3%$13.26$8.73▼$16.79$11.09B1.26.19 million shs1.16 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+0.21%+3.98%+3.53%-6.71%-11.65%INSMInsmed-0.31%+9.87%+10.31%+67.40%+126.72%ONCBeOne Medicines+2.77%+4.75%+1.34%+38.56%+35,108,999,900.00%ROIVRoivant Sciences-0.56%+1.78%+24.17%+38.55%+42.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.64Moderate Buy$134.4627.43% UpsideINSMInsmed 2.86Moderate Buy$149.06-8.88% DownsideONCBeOne Medicines 2.90Moderate Buy$340.300.99% UpsideROIVRoivant Sciences 2.80Moderate Buy$19.9422.81% UpsideCurrent Analyst Ratings BreakdownLatest ROIV, ONC, INSM, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$345.00 ➝ $385.0010/8/2025ONCBeOne MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ROIVRoivant SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/3/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $196.0010/2/2025INSMInsmedCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/2/2025INSMInsmedTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$154.00 ➝ $193.0010/1/2025INSMInsmedEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$180.009/27/2025BNTXBioNTechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025INSMInsmedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ONCBeOne MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B8.52N/AN/A$87.61 per share1.20INSMInsmed$398.11M86.86N/AN/A$1.60 per share102.24ONCBeOne Medicines$3.81B9.69N/AN/A$34.10 per share9.88ROIVRoivant Sciences$23.23M477.19N/AN/A$7.45 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)ONCBeOne Medicines-$644.79M-$1.73N/A474.62N/A-3.89%-1.22%-0.72%N/AROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest ROIV, ONC, INSM, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025BNTXBioNTech$0.57N/AN/AN/A$1.21 billionN/A10/30/2025Q3 2025INSMInsmed-$1.35N/AN/AN/A$114.33 millionN/A8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025ONCBeOne Medicines$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billion8/4/2025Q2 2025BNTXBioNTech-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.618.48INSMInsmed0.456.686.33ONCBeOne Medicines0.041.951.72ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/AONCBeOne Medicines48.55%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed3.00%ONCBeOne Medicines6.62%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.40 million194.24 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableONCBeOne Medicines11,000109.60 million102.34 millionN/AROIVRoivant Sciences860682.88 million609.13 millionOptionableROIV, ONC, INSM, and BNTX HeadlinesRecent News About These CompaniesEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9 at 5:34 AM | insidertrades.comWeiss Ratings Reaffirms "Sell (D+)" Rating for Roivant Sciences (NASDAQ:ROIV)October 9 at 4:58 AM | marketbeat.comValeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIVOctober 8 at 4:25 AM | marketbeat.comRoivant Sciences Rises on Nasdaq Composite with Strong MomentumOctober 7 at 3:55 PM | kalkinemedia.comKRoivant Sciences (NASDAQ:ROIV) Sets New 12-Month High - Should You Buy?October 7 at 7:12 AM | marketbeat.comWhy Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst UpgradesOctober 4, 2025 | finance.yahoo.comElevate Capital Advisors LLC Sells 61,368 Shares of Roivant Sciences Ltd. $ROIVOctober 4, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Buy" from BrokeragesOctober 2, 2025 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High - Here's What HappenedOctober 1, 2025 | marketbeat.comLVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIVSeptember 29, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from AnalystsSeptember 27, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeptember 25, 2025 | seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 416,182 Shares of StockSeptember 24, 2025 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 SharesSeptember 23, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 SharesSeptember 23, 2025 | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 683,818 Shares of StockSeptember 23, 2025 | marketbeat.comAre You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd.September 23, 2025 | zacks.comRoivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call TranscriptSeptember 23, 2025 | seekingalpha.comBrokers Issue Forecasts for ROIV Q1 EarningsSeptember 22, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for ROIV EarningsSeptember 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNuScale, Rocket Lab Face Heavy Insider Selling After SurgesBy Leo Miller | September 26, 2025Is It Time to Trim Your Positions in These 2 AI Stocks?By Jordan Chussler | September 16, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025RH Stock Slides After Mixed Earnings and Tariff ConcernsBy Chris Markoch | September 14, 2025Forget QQQ: This ETF Marries the Magnificent 7 and CommunicationsBy Jordan Chussler | September 10, 2025ROIV, ONC, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$105.52 -0.76 (-0.72%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$163.59 +1.78 (+1.10%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.BeOne Medicines NASDAQ:ONC$336.98 -14.11 (-4.02%) As of 11:07 AM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Roivant Sciences NASDAQ:ROIV$16.24 +0.21 (+1.28%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
